Trial · NCT04616729
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in ovarian volume | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A transvaginal ultrasound will be performed to measure the ovarian volume according to the formula 'length x width x height x 0.523' mm³. In the assumption of safety ovarian volume should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in hematocrit | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate hematocrit (%). In the assumption of safety hematocrit levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in hemoglobine | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate hemoglobine (g/dL). In the assumption of safety hemoglobine levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in White Blood cell Count | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate White Blood cell Count (X10³/mm³). In the assumption of safety White Blood cell Count should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Platelet Count | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate Platelet Count (X10³/mm³). In the assumption of safety Platelet Count should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in estimated glomerular filtration rate (eGFR) | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate eGFR (mL/min/1.73m²). In the assumption of safety eGFR levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Creatinine | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate Creatinine (mg/dL). In the assumption of safety creatinine levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Albumin | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate Albumin (g/L). In the assumption of safety Albumin levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in liver function (AST, ALT, Gamma-GT, bilirubine, LDH) | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate liver function (AST U/L, ALT U/L, Gamma-GT U/L, bilirubine mg/dL, LDH U/L). In the assumption of safety liver function levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Oestradiol (E2) | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate Oestradiol (ng/L). In the assumption of safety Oestradiol levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Progesteron | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate Progesteron (mcg/L). In the assumption of safety Progesteron levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Follicle Stimulating Hormone (FSH) | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate FSH (IU/L). In the assumption of safety FSH levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Luteinizing Hormone (LH) | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate LH (IU/L). In the assumption of safety LH levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Secondary | Number of cumulus-oocyte complexes | During the procedure of the transvaginal oocyte retrieval | Evaluation of the number of cumulus-oocyte complexes between the Depot Group and Daily Group |
| Secondary | Number of Metaphase II oocytes | Immediately after the procedure of the transvaginal oocyte retrieval | Evaluation of the number of Metaphase II oocytes between the Depot group and Daily group |
| Secondary | Evaluation of climacteric symptoms | One week after the transvaginal oocyte retrieval (on day 7) | Assessment of MENQOL (The Menopause-Specific Quality of Life) Questionnaire |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04616729/registered